Bezlotoxumab for Prevention of RecurrentClostridium difficileInfection
Top Cited Papers
- 26 January 2017
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 376 (4), 305-317
- https://doi.org/10.1056/nejmoa1602615
Abstract
Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy. Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively.This publication has 32 references indexed in Scilit:
- Relationship Between Bacterial Strain Type, Host Biomarkers, and Mortality in Clostridium difficile InfectionClinical Infectious Diseases, 2013
- Antibody Against TcdB, but Not TcdA, Prevents Development of Gastrointestinal and Systemic Clostridium difficile DiseaseThe Journal of Infectious Diseases, 2012
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus VancomycinClinical Infectious Diseases, 2012
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDIClinical Infectious Diseases, 2012
- Prediction Tools for Unfavourable Outcomes in Clostridium difficile Infection: A Systematic ReviewPLOS ONE, 2012
- Treatment with Monoclonal Antibodies againstClostridium difficileToxinsNew England Journal of Medicine, 2010
- Toxin B is essential for virulence of Clostridium difficileNature, 2009
- A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease SeverityClinical Infectious Diseases, 2007
- Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile -Induced Mortality in HamstersInfection and Immunity, 2006
- Stool Form Scale as a Useful Guide to Intestinal Transit TimeScandinavian Journal of Gastroenterology, 1997